Epithelial-mesenchymal transition (EMT) has been linked with aggressive tumor biology and therapy resistance. It plays central role not only in the generation of cancer stem cells (CSCs) but also direct them across the multiple organ systems to promote tumor recurrence and metastasis. CSCs are reported to express stem cell genes as well as specific cell surface markers and allow aberrant differentiation of progenies. It facilitates cancer cells to leave primary tumor, acquire migratory characteristics, grow into new environment and develop radio-chemo-resistance. Based on the current information, present review discusses and summarizes the recent advancements on the molecular mechanisms that derive epithelial plasticity and its major role in generating a subset of tumor cells with stemness properties and pathophysiological spread of tumor. This paper further highlights the critical need to examine the regulation of EMT and CSC pathways in identifying the novel probable therapeutic targets. These improved therapeutic strategies based on the co-administration of inhibitors of EMT, CSCs as well as differentiated tumor cells may provide improved antineoplastic response with no tumor relapse.
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INTRODUCTION
Despite significant advancements in standard treatment modalities including surgical resection, radio and che motherapeutic procedures to treat cancer, there has been a tremendous increase in cancer related deaths globally. Although current therapeutic strategies have been successfully implicated and resulted improved tolerance and organ preservation in patients with locally advanced cancer but fail to prevent tumor from relapse. Therapeutic resistance leads to cancer pathogenesis, tumor recurrence and metastasis.
Accumulation of multiple genomic mutations in cells leads to genetic instability or oncogeneinduced plasticity. Genetic and epigeneticchangesmay transform normal stem cells, differentiated cells or progenitor cells into cancer stem cells (CSCs) and allow the de velopment of tumors. Existence of quiescent CSCs has been reported during intense growth of tumor and examined to possess the potential to selfrenew, ability to proliferate and aberrantly differentiate into heterogeneous lineages of cancer cells. Cancer cells leave primary tumor site, extravasate to distant organs through blood or lymphatic system, colonize into new environment and develop resistance to therapeutic drugs.
Dissolution of intercellular adhesions and loss of epithelial polarity as a result of epithelialmesenchy mal transition (EMT) program has been associated with uncontrolled proliferation of cells and malignant progression. EMT regulates the apicobasal polarity of epithelial cells and turns them into cells with me senchymal traits. Eventually cancer cells proliferate extensively, invade, acquire migratory capabilities and metastasize. Altered epithelial functions enable the CSCs to survive and exhibit resistance to growth inhibitory drugs thereby contributes to long term tumor recurrence and cancer progression.
Understanding the molecular mechanisms that control cancer pathobiology and therapeutic resistance may allow us to identify the biomarkers of potential clinical significance and novel therapeutic targets to treat cancer for their effective eradication and improved clinical outcomes. This paper summarizes the major findings on mechanistic regulation of EMT that transforms stem cells into CSCs, its major functions in metastatic activities, drug resistance and therapeutic implications.
EPITHELIAL PLASTICITY
EMT program is classified as EMT type 1, EMT type 2 and EMT type 3 and considered as an important physiolo gical phenomenon in organogenesis during embryonic development, wound healing and cancerrespectively [1] . It is characterized by the chain of events that starts from cells' inside to extracellular matrix (ECM) and includes loss of epithelial cellcell junctions and cell polarity, stress fiber redistribution and transition from epithelial phenotype to mesenchymal (fibroblastic) phenotype. Epithelial tumor cells exhibit cellular plasticity, undergo transition from epithelial (E) to mesenchymal (M) phenotype, dismantle basement membrane, infiltrate the surrounding tissues and metastasize to distant sites. This is followed by the growth of secondary tumors and regain of epithelial characteristics,required during differentiation through the activation of reverse programmesenchymal to epithelial transition (MET) [2] ( Figure 1 ).
Cellular dissociation, morphological change to more prolonged forms and increased migration abilities of cells are described by molecular characteristics which include increased expression of Ncadherin, vimentin, type 1 collagen, βcatenin stabilization, repression of Ecadherin, claudins, zona occludens 1, occludins, cytokeratins, base ment membrane components collagen Ⅳ and laminin 1 and release of matrix remodeling enzymes (matrix metalloproteinases). Molecular changes in the basic foundations in epithelial architecture are noted as a result of induction of EMTactivating transcription factors (EMTATFs) such as twohanded zincfinger factors of dcrystallin/E2 box factor 1 (dEF1) family proteins, EF1/ZEB1 [dEF1/zincfingerEboxbinding homeobox 1 (ZEB1)] and SIP1 (Smadinteracting protein)/ZEB2, Snail family of zincfinger transcription factors, Snail1 (Snail), Snail2 (Slug) and Snail 3 (Smuc), basic helix loophelix factors, Twist and E12/E47. Wnt, smad3 dependent transforming factorbeta (TGFβ), Hedgehog, Notch, fibroblast growth factor (FGF), epidermal growth factor (EGF), insulin growth factor (IGF), hepatocyte growth factor (HGF), plateletderived growth factor (PDGF), estrogens, sonic hedgehog (Shh), and nuclear factorκB (NFκB) signaling pathways are regulated by microenvironmental stimuli and act as EMT in ducers [3, 4] (Figure 2 ). Besides the cooperation between signaling pathways through autocrine signaling loops, inflammatory cytokines, hypoxic or oncogenic signals also contribute to EMT during cancer progression. Change in the expression of several microRNAs (mi RNAs) has been observed during induction of EMT or MET. MicroRNAs are 2123 nucleotide long nonencoding RNA molecules, modulate gene expression posttranscriptionally and act as master regulator in many pathological and physiological processes including tumor development. Suppression of Ecadherin through direct targeting of its transcriptional repressors and hence inhibition of EMT has been associated with the expression of miR200 family, miR205, miR34 family [57] . (Figure 3 ).
As per the tumor progression model described by Brabletz et al [9] , migrating CSCs with stemlike characteristics at tumorhost interface acquire migratory capacities through EMT and are responsible for the formation of primary tumor, metastatic dissemination of cancer cells, recurrence and therapeutic resistance.
CSCs
Theory of CSCs and the fact that cancer arises from the rare subset of cells with stemness properties was conceptualized around 150 years ago. Small population of tumor cells expressing specific surface markers including CD34 + and CD38 in human acute myeloid leukemia has been identified as CSCs or cancer initiating cells (CICs) by Bonnet and Dick [10] . These cancer cells were later described in other tumors including head and neck, breast, prostate, lung, liver, pancreas, colon and bladder. CSCs and stem cells share similarities in terms of expression of specific surface markers, regulation by stem cell niche and signaling pathways as well as their selfrenewal abilities. Tumorigenic activities exhibited by CSCs allow them to differ significantly from normal stem cells. Studies from hematological as well as solid organ malignancies characterize CSCs with the ability to mediate angiogenesis, develop tumor upon their serial transplantation into immunodeificient mice and tumorsphere formation in nonadherent 3D cultures [11, 12] . The other hallmark feature of CSCs reported is aberrant differentiation where these cells undergo asymmetrical division to produce nontumo rigenic population of cells and symmetrical division to develop tumorigenic daughter cells.
Regulation of CSCs, stemness properties and their enhanced migratory characteristics has been shown to be orchestrated by the interplay of complex pathways and various transcription factors. Hedgehog, Notch, Wnt/betacatenin, octamerbinding transcription factor 4 (Oct4), SRY (sexdetermining region Y)box 2 (Sox2) and Kruppellike factor 4 (Klf4), highmobility group AT hook 2 (HMGA2), Nanog, Nestin, Bcl2, Bmi1, cMyc, and cMetare required for the differentiated cells to reprogram to pluripotent stem cells, drive the production and maintenance of pluripotent cells with stemness properties [1315] . Crosstalk between pleiotropically acting molecules, EMT associated genes and transcriptional mediators such as Snail/Twist or TGFβ treatment has been linked with expression of tumor cells with CD44 + / CD24 surface markers, enhanced mammosphere formation and induction of EMT in immortalized human mammary epithelial cells [16] . [17] . Experimental studies underline the important functions of EMT in the generation of CSCs and conferring self renewal ability to the differentiated tumor cells. Transition from E to M phenotype contributes to the enhanced migration of CSCs, their dissemination in the circulation and colonization to a particular site. Thus migratory CSCs form secondary metastatic nodules and exhibit E phenotype via MET [18, 19] . EMT gradient model describes the bimodal nature of EMT program in epithelial cells. Cancer cells with E phenotype display stemness properties during early stage of tumor development but loose it when they acquire M phenotype. Nevertheless robust association of hybrid E/M phenotype of cancer cells that coexpress epithelial and mesenchymal markers through the pa rtial activation of EMT program has been examined with increased stemness, plasticity, selfrenewability, migration capabilities and poor cancer outcomes ( Figure  1 ). Role of phenotypic stability factors (PSFs) including OVOL and GRHL2 has been characterized in stabilization of E/M hybrid state when coupled with miR200/Zeb (EMTdecision making circuit) [20] . miR200 by inhibiting LIN28; NFκB, but not cMyc by regulating LIN28/let7; and OVOL by coupling with miR200/ZEB/LIN28/let7 circuit have been examined to increase the stemness of the hybrid E/M phenotype [21, 22] (Figure 3 ).
Breast CSCs with E/M hybrid behavior are examined to show increased ALDH1 + (aldehyde dehydrogenase 1) activity, mammosphere formation, selfrenewal capability and stemness as compared to highly differentiated M cells that exhibit less cellular plasticity and E cells which show less selfrenewability [23, 24] . Subset of ovarian cancer cells with hybrid E/M state has been identified with low membranous and high cytoplasmic Ecadherin, high CD133, high CD44, low Tie2 expression, increased plasticity and in vivo xenograft tumor growth upon their transformation [25] . Epithelial plasticity thereby facilitates metastasis formation, confers long term survival advan tages to the disseminated cancer cells at distant sites, makes tumor cells resistant to conventional therapies and allows the cancer to relapse.
THERAPEUTIC IMPLICATIONS
Chemotherapy and radiotherapy as noninvasive as well as surgical resection or the combination of these are the most commonly used cancer therapies in clinics. These therapies although can be employed to kill bulk of the tumor and provide maximal benefit to the overall survival of the patients, nevertheless, therapies have always been associated with systemic or local toxicity, aggressive cancer relapse and drug resistance. Population of pancreatic cancer cells ex hibiting resistance to gemcitabine, ovarian carcinoma cells to paclitaxel, breast cancer cells to tamoxifen or lapatinib, lung cancer cells to gefitinib have been identified with the coexistence of subset of cancer cells, CSCs with mesenchymal traits and multiple resistant mechanisms associated with them [2628] . Relative dor mant behavior, high expression of antiapoptosis proteins and multiple drug resistance membrane trans porters, epithelial plasticity, hypoxia are some of the potential reasons of CSCs' survival and therapeutic failure. Use of combinational approaches to target EMT which is responsible for the survival of CSCs and their tumor functions offers new possible strategy for cancer therapy. Multiple powers of EMT have crystal lized an emerging concept of differentiation based cancer therapies as attractive targets for therapeutic intervention (Figure 4) .
Prevention of STAT3mediated transcription of ZEB1, SNAI1 via suppression of JAK1/2 by ruxolitinib and ZEB1 silencing through shRNAmediated knockdown in oncostatin M (OSM, an IL6 cytokine family member) driven mesenchymal/CSC phenotype has been exa mined to revert it back to an epithelial/nonCSC state in pancreatic ductal adenocarcinoma [29] . Dai et al [30] studied the therapeutic effects of ascochlorin (ASC) in increasing sensitivity to doxorubicin treatment through inhibiting STAT3 binding to the Snail promoter, reverting EMT phenotype, inhibiting metastasis in the treatment of hepatocellular carcinoma.
Delivery of antimiR145 using polyurethaneshort branchPEI (PUPEI) to the mice bearing xenograft tumors has been examined to regulate Oct4/Sox2/ Fascin1, Tcf4 (immunoglobulin transcription factor 4, also known as E22) and Wnt5a, inhibit EMT and metastatic potential and sensitize lung adenocarcinoma CSCs to chemo and radio therapeutic drugs [31] . Forced expression of miR200 family has been validated to restore the sensitivity of EGFR inhibitor, induces MET in mesenchymal bladder cancer cell lines, reduces tumor aggressiveness and metastatic spread [32] . Study by Luo et al [33] reports the reduced expression levels of CSCs markers LIN28B, Nanog, Oct4, and Notch1; lower expression of EMT markers MMP2, MMP3, MMMP9, Figure 4 Cancer stem cells, epithelial plasticity and therapeutic strategies. A: Existence of quiescent CSCs that possess the potential to self-renew, ability to proliferate and aberrantly differentiate into heterogeneous lineages of cancer cells and tumor microenvironment by creating immunosuppressive environment regulate epithelial plasticity and enable CSCs to survive, exhibit resistance to growth inhibitory drugs and cause tumor to progress; B: Therapeutic strategies including delivery of miRNA mimics to enforce the expression of tumor suppressor genes, administration of anti-miRNAs to downregulate the expression of oncogenes, shRNA mediated knockdown of oncogenic factors to revert the mesenchymal/CSC phenotype to epithelial non-CSC phenotype and creating inhospitable tumor microenvironment not only confer therapeutic check on epithelial plasticity but also sensitize cancer stem cell populations to the killing effects of therapeutic drugs. CSC: Cancer stem cell; miRNAs: MicroRNAs; ShRNA: Short hairpin RNA.
SNAIL, TWIST, Vimentin; increased expression of
Ecadherin and βcatenin, and reduced sphere formation through siRNA mediated knockdown of NR5A2 (pancreatic cancer susceptibility gene) in pancreatic cancer [33] . Clinical value of valproic acid (VPA), histone deace tylase (HDAC) inhibitor has been investigated to suppress irradiationinduced EMT, attenuate cell invasion, migration abilities and improve the effectiveness of radiotherapy in the treatment of esophageal squamous cell carcinoma (ESCC) TE9 cells [34] . Angiopoietinlike protein 1 (ANGPTL1) has been examined to reduce EMTdriven sorafenib resistance and cancer stemness properties of hepatocellular carcinoma cells through the inactivation of MET-extracellular receptor kinase/protein kinase B-dependent early growth response protein 1Slug (MET receptorAKT/ERKEgr1Slug) signaling cascade [35] . Reduced expression levels of EMTATFs including SNAI2; selfrenewal genes Nanog and BMI1; low activity of ALDH; low ratio of CDH1 (Ecadherin) and CDH2 (Ncadherin), reduced invasion and metastatic growth are the observed therapeutic effects as a result of targeting αv integrins in bladder cancer cell lines [36] . Tumor microenvironment and its associated factors create immunosuppressive environment, regulate the plasticity program and determine the metastatic capacity and therapeutic resistance. Prolonged stimulation of hypoxia conditions and increased hypoxia inducing factor1α (HIF1α) expression identifies and isolates breast cancer stem cells (BCSCs) with ALDH activity (CD44 + /CD24 /Aldefluor pos ). Further knockdown of HIF 1α has been shown to cause significant loss of stem cell properties through the reduction in the expression of mRNA genes associated with EMT (Snail, Slug and Vimentin low and Ecadherin high) and may influence breast cancer clinical outcomes [37] . Inhibition of growth, migration and reduced radioresistance of NPCSC (nasopharyngeal carcinoma CNE2 stemlike cell) has been observed to be a consequence of exposure of these cells with 2Methoxyestradiol (2ME2), a metabolic product of estrogen and Xray. 2ME2 has been reported to decrease NFκB p65 and HIF1α protein expression levels, downregulate NFκB p65 nuclear localization and reversion of EMT [38] . Experimental studies identify novel connection between the pharmacological targeting of signaling molecules that contribute to cancer stemlike and EMT Garg M. Epithelial plasticity in cancer progression and therapy resistance phenotype, restrained cancer stem cell growth, inhibition of selfrenewability and reduced metastatic growth in vitro as well as in vivo. Creating an inhospitable microenvironment around the protective niche of CSCs through therapeutic check on epithelial plasticity may provide the basis for developing improved therapeutic strategy in complete elimination of CSCs and bulk tumor population at primary and distant sites [3953] (Table 1) .
Unravelling the complex interplay of molecules and understanding the functions of miRNAmRNA inter actions complex in cellular plasticity that influence the biology of CSCs, high throughput screening of drugs in combination and their clinical utility, development of effective and safe systems for the delivery of synthetic miRNA precursors in clinically relevant animal models are the major challenging issues in the development of therapeutics and their translation into clinical setting.
CONCLUSION
Frequently observed reason for the failure in the treatment of malignant carcinomas is the biological programming of epithelial cells called EMT. EMT confers cancer cells, an ability to lose epithelial traits; gain mesenchymal traits; acquire stemlike properties; disseminate and colonize to distant organ sites and show elevated resistance to cancer therapies. Aberrant activation of signaling pathways including Wnt/betacatenin, hedgehog, Notch, receptor tyrosine kinase, TNFα, TGFβ has critical roles in EMT. Number of experimental studies reports the regulatory effect of miRNAs on the cross talk of these pathways, EMT, generation of CSCs, cancer invasion and metastasis.
Partial elimination of CSCs and their propagation into secondary tumors posttreatment are the limitations associated with currently available standard of care including radio/chemotherapies, surgical resection or combination of these. Recent research studies come up with alternate form of therapies that can directly target, eliminate CSCs and decrease tumor relapse. Differentiationbased therapeutic strategies utilize the variable and regulatory powers of EMT program, lead to successful eradication of stemlike population of cancer cells by reverting the EMT phenotype and may hold great promise in improving the clinical outcomes.
